Latest News and Press Releases

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...

 Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025. Introducing LLibra OS, a next-generation AI platform that accelerates discovery and...

ADARx Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

 Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc....

Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Market by Technology, Route of Administration, Application, and Region 2025-2033" has been added to ...

ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 ...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia RNA Therapeutics Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's...

New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA...

Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "RNAi Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's...

Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- The "RNA Interference Market by Type, by Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering.The global...